Compare CTBI & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTBI | ORIC |
|---|---|---|
| Founded | 1903 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2020 |
| Metric | CTBI | ORIC |
|---|---|---|
| Price | $61.47 | $12.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $59.00 | $19.73 |
| AVG Volume (30 Days) | 70.7K | ★ 1.7M |
| Earning Date | 01-21-2026 | 02-17-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ 17.79 | N/A |
| EPS | ★ 5.43 | N/A |
| Revenue | ★ $270,159,000.00 | N/A |
| Revenue This Year | $13.17 | N/A |
| Revenue Next Year | $5.92 | N/A |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | ★ 13.70 | N/A |
| 52 Week Low | $44.60 | $3.90 |
| 52 Week High | $65.48 | $14.93 |
| Indicator | CTBI | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 57.89 | 68.34 |
| Support Level | $60.76 | $11.52 |
| Resistance Level | $65.48 | $12.61 |
| Average True Range (ATR) | 1.64 | 0.83 |
| MACD | 0.26 | 0.33 |
| Stochastic Oscillator | 55.14 | 86.92 |
Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and southcentral Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.